A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Roniciclib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 29 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as development of BAY1000394 has been terminated by Bayer.
- 28 Jan 2016 New trial record